UA72198C2 - Hydrate 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidyn -2, 4-dione, maleic acid salts as pharmaceutical preparation - Google Patents

Hydrate 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidyn -2, 4-dione, maleic acid salts as pharmaceutical preparation Download PDF

Info

Publication number: UA72198C2
Authority: UA; Ukraine
Prior art keywords: hydrate; hydrate according; dione; pyridyl; ethoxy
Prior art date: 1997-12-16

Application number

UA2000063485A

Other languages

English (en)

Ukrainian (uk)

Inventor

Paul David James Blackler

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-16

Filing date

1998-12-14

Publication date

2005-02-15

1998-12-14 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2005-02-15 Publication of UA72198C2 publication Critical patent/UA72198C2/uk

Links

125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title claims description 13
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title claims description 9
150000002688 maleic acid derivatives Chemical class 0.000 title abstract 2
239000000825 pharmaceutical preparation Substances 0.000 title description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
238000000034 method Methods 0.000 claims abstract description 10
239000000126 substance Substances 0.000 claims abstract description 9
238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 8
238000001237 Raman spectrum Methods 0.000 claims abstract description 6
238000002329 infrared spectrum Methods 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
206010012601 diabetes mellitus Diseases 0.000 claims description 18
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 6
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
239000011976 maleic acid Substances 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
HAFWELDDNUXLCK-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrate Chemical compound O.OC(=O)\C=C/C(O)=O HAFWELDDNUXLCK-ODZAUARKSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
238000002441 X-ray diffraction Methods 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 abstract description 23
239000000203 mixture Substances 0.000 abstract description 16
239000003814 drug Substances 0.000 abstract description 3
238000002360 preparation method Methods 0.000 abstract description 3
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000002904 solvent Substances 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 9
208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
150000002689 maleic acids Chemical class 0.000 description 5
206010022489 Insulin Resistance Diseases 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229940075894 denatured ethanol Drugs 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020710 Hyperphagia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000005388 cross polarization Methods 0.000 description 1
239000011928 denatured alcohol Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
201000000523 end stage renal failure Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
-1 for example Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000004104 gestational diabetes Diseases 0.000 description 1
239000011521 glass Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
201000009925 nephrosclerosis Diseases 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
235000020830 overeating Nutrition 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008063 pharmaceutical solvent Substances 0.000 description 1
201000010065 polycystic ovary syndrome Diseases 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000002791 soaking Methods 0.000 description 1
229940023144 sodium glycolate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UA2000063485A 1997-12-16 1998-12-14 Hydrate 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidyn -2, 4-dione, maleic acid salts as pharmaceutical preparation UA72198C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9726566.4A GB9726566D0 (en)	1997-12-16	1997-12-16	Novel pharmaceutical
PCT/EP1998/008155 WO1999031095A1 (en)	1997-12-16	1998-12-14	5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical

Publications (1)

Publication Number	Publication Date
UA72198C2 true UA72198C2 (en)	2005-02-15

Family

ID=10823692

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000063485A UA72198C2 (en)	1997-12-16	1998-12-14	Hydrate 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidyn -2, 4-dione, maleic acid salts as pharmaceutical preparation

Country Status (35)

Country	Link
EP (2)	EP1661895A1 (ar)
JP (1)	JP2002508373A (ar)
KR (1)	KR100549142B1 (ar)
CN (3)	CN1281453A (ar)
AP (1)	AP1365A (ar)
AR (1)	AR017214A1 (ar)
AU (1)	AU1967999A (ar)
BG (1)	BG64988B1 (ar)
BR (1)	BR9813600A (ar)
CA (1)	CA2314107A1 (ar)
CO (1)	CO4980880A1 (ar)
CZ (1)	CZ299965B6 (ar)
DZ (1)	DZ2681A1 (ar)
EA (1)	EA004260B1 (ar)
EG (1)	EG22337A (ar)
GB (1)	GB9726566D0 (ar)
HR (1)	HRP20000408B1 (ar)
HU (1)	HUP0100509A3 (ar)
IL (1)	IL136424A (ar)
IN (1)	IN192487B (ar)
MA (1)	MA26580A1 (ar)
MY (1)	MY135612A (ar)
NO (1)	NO317254B1 (ar)
OA (1)	OA11766A (ar)
PE (1)	PE20000058A1 (ar)
PL (1)	PL341146A1 (ar)
RS (1)	RS50126B (ar)
SA (1)	SA99191115B1 (ar)
SK (1)	SK286618B6 (ar)
TR (2)	TR200001799T2 (ar)
TW (1)	TW509690B (ar)
UA (1)	UA72198C2 (ar)
UY (2)	UY25304A1 (ar)
WO (1)	WO1999031095A1 (ar)
ZA (1)	ZA9811506B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6664278B2 (en)	1997-12-16	2003-12-16	Smithkline Beecham P.L.C.	Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en)	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel pharmaceutical
GB9909041D0 (en) *	1999-04-20	1999-06-16	Smithkline Beecham Plc	Novel pharmaceutical
HUP0200929A3 (en) *	1999-04-23	2004-03-29	Smithkline Beecham Plc	Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
CO5170419A1 (es) *	1999-04-23	2002-06-27	Smithkline Beecham Plc	Nuevo compuesto antidiabetico con base en sales del acido maleico
PE20010044A1 (es) *	1999-04-23	2001-03-10	Smithkline Beecham Plc	Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidina-2,4-diona
EA004244B1 (ru) *	2000-04-25	2004-02-26	Киорин Фармасьютикал Ко., Лтд.	Новый стабильный кристалл производного тиазолидиндиона и способ его получения
GB0014005D0 (en) *	2000-06-08	2000-08-02	Smithkline Beecham Plc	Novel pharmaceutical
GB0021784D0 (en) *	2000-09-05	2000-10-18	Smithkline Beecham Plc	Novel pharmaceutical
GB0021978D0 (en) *	2000-09-07	2000-10-25	Smithkline Beecham Plc	Novel pharmaceutical
JP2004509961A (ja) *	2000-09-26	2004-04-02	ドクター・レディーズ・リサーチ・ファウンデーション	５−［４−［２−［ｎ−メチル−ｎ−（２−ピリジル）アミノ］エトキシ］ベンジル］チアゾリジン−２，４−ジオンマレイン酸塩の新規の多型形態およびそれらの調製方法
AU2002350965A1 (en) *	2001-12-13	2003-06-23	Smithkline Beecham Plc	Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB0129876D0 (en) *	2001-12-13	2002-02-06	Smithkline Beecham Plc	Novel pharmaceutical
GB2405403A (en) *	2003-08-29	2005-03-02	Cipla Ltd	Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) *	2004-07-28	2004-10-28	Chemi Spa	Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) *	2005-05-24	2007-09-26	Zentiva, A. S.	Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en)	2008-11-07	2010-05-12	LEK Pharmaceuticals d.d.	Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0842925A1 (en) *	1987-09-04	1998-05-20	Beecham Group Plc	Substituted thiazolidinedione derivatives
GB8820389D0 (en) *	1988-08-26	1988-09-28	Beecham Group Plc	Novel compounds
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
WO1995021608A1 (en) *	1994-02-10	1995-08-17	Smithkline Beecham Plc	Use of insulin sensitisers for treating renal diseases

1997
- 1997-12-16 GB GBGB9726566.4A patent/GB9726566D0/en not_active Ceased
1998
- 1998-12-14 PL PL98341146A patent/PL341146A1/xx not_active Application Discontinuation
- 1998-12-14 HU HU0100509A patent/HUP0100509A3/hu unknown
- 1998-12-14 AU AU19679/99A patent/AU1967999A/en not_active Abandoned
- 1998-12-14 MA MA25389A patent/MA26580A1/fr unknown
- 1998-12-14 TR TR2000/01799T patent/TR200001799T2/xx unknown
- 1998-12-14 JP JP2000539019A patent/JP2002508373A/ja not_active Withdrawn
- 1998-12-14 KR KR1020007006515A patent/KR100549142B1/ko not_active IP Right Cessation
- 1998-12-14 CZ CZ20002204A patent/CZ299965B6/cs not_active IP Right Cessation
- 1998-12-14 EP EP05077331A patent/EP1661895A1/en not_active Withdrawn
- 1998-12-14 CN CN98812089A patent/CN1281453A/zh active Pending
- 1998-12-14 EA EA200000654A patent/EA004260B1/ru not_active IP Right Cessation
- 1998-12-14 AP APAP/P/2000/001831A patent/AP1365A/en active
- 1998-12-14 IL IL13642498A patent/IL136424A/xx unknown
- 1998-12-14 CA CA002314107A patent/CA2314107A1/en not_active Abandoned
- 1998-12-14 SK SK917-2000A patent/SK286618B6/sk not_active IP Right Cessation
- 1998-12-14 CN CNA2008100870305A patent/CN101302215A/zh active Pending
- 1998-12-14 OA OA1200000178A patent/OA11766A/en unknown
- 1998-12-14 WO PCT/EP1998/008155 patent/WO1999031095A1/en active IP Right Grant
- 1998-12-14 CN CNA200810087031XA patent/CN101381367A/zh active Pending
- 1998-12-14 UA UA2000063485A patent/UA72198C2/uk unknown
- 1998-12-14 EP EP98964510A patent/EP1040110A1/en not_active Withdrawn
- 1998-12-14 RS YUP-363/00A patent/RS50126B/sr unknown
- 1998-12-14 BR BR9813600-3A patent/BR9813600A/pt not_active Application Discontinuation
- 1998-12-15 UY UY25304A patent/UY25304A1/es unknown
- 1998-12-15 ZA ZA9811506A patent/ZA9811506B/xx unknown
- 1998-12-15 AR ARP980106370A patent/AR017214A1/es unknown
- 1998-12-15 MY MYPI98005674A patent/MY135612A/en unknown
- 1998-12-15 EG EG155698A patent/EG22337A/xx active
- 1998-12-15 DZ DZ980291A patent/DZ2681A1/xx active
- 1998-12-15 UY UY25308A patent/UY25308A1/es not_active IP Right Cessation
- 1998-12-16 PE PE1998001233A patent/PE20000058A1/es not_active Application Discontinuation
- 1998-12-16 TR TR1998/02625A patent/TR199802625A3/tr unknown
- 1998-12-16 TW TW087121121A patent/TW509690B/zh not_active IP Right Cessation
- 1998-12-16 CO CO98074834A patent/CO4980880A1/es unknown
- 1998-12-16 IN IN3772DE1998 patent/IN192487B/en unknown
1999
- 1999-02-27 SA SA99191115A patent/SA99191115B1/ar unknown
2000
- 2000-06-15 NO NO20003069A patent/NO317254B1/no not_active IP Right Cessation
- 2000-06-16 HR HR20000408A patent/HRP20000408B1/xx not_active IP Right Cessation
- 2000-07-13 BG BG104603A patent/BG64988B1/bg unknown

Also Published As

Publication number	Publication date
IL136424A0 (en)	2001-06-14
CO4980880A1 (es)	2000-11-27
SK9172000A3 (en)	2001-01-18
DZ2681A1 (fr)	2004-06-20
CN1281453A (zh)	2001-01-24
UY25308A1 (es)	1999-07-19
AP1365A (en)	2005-01-26
HUP0100509A2 (hu)	2002-05-29
BG104603A (en)	2001-03-30
IN192487B (ar)	2004-04-24
AU1967999A (en)	1999-07-05
CN101381367A (zh)	2009-03-11
ZA9811506B (en)	2000-11-06
NO20003069L (no)	2000-06-15
EP1661895A1 (en)	2006-05-31
RS50126B (sr)	2009-03-25
AR017214A1 (es)	2001-08-22
EG22337A (en)	2002-12-31
NO317254B1 (no)	2004-09-27
CZ20002204A3 (cs)	2000-11-15
UY25304A1 (es)	2000-12-29
EA200000654A1 (ru)	2000-12-25
CN101302215A (zh)	2008-11-12
AP2000001831A0 (en)	2000-06-30
PL341146A1 (en)	2001-03-26
TW509690B (en)	2002-11-11
GB9726566D0 (en)	1998-02-11
HRP20000408A2 (en)	2000-08-31
JP2002508373A (ja)	2002-03-19
BG64988B1 (bg)	2006-11-30
HUP0100509A3 (en)	2002-06-28
BR9813600A (pt)	2000-10-10
KR20010033141A (ko)	2001-04-25
WO1999031095A1 (en)	1999-06-24
CZ299965B6 (cs)	2009-01-07
TR199802625A2 (xx)	1999-10-21
IL136424A (en)	2003-12-10
NO20003069D0 (no)	2000-06-15
YU36300A (sh)	2004-03-12
TR199802625A3 (tr)	1999-10-21
EP1040110A1 (en)	2000-10-04
TR200001799T2 (tr)	2001-01-22
OA11766A (en)	2005-07-19
SK286618B6 (sk)	2009-02-05
SA99191115B1 (ar)	2006-10-11
EA004260B1 (ru)	2004-02-26
PE20000058A1 (es)	2000-02-26
CA2314107A1 (en)	1999-06-24
MY135612A (en)	2008-05-30
KR100549142B1 (ko)	2006-02-03
MA26580A1 (fr)	2004-12-20
HRP20000408B1 (en)	2008-04-30

Publication	Publication Date	Title
UA72198C2 (en)	2005-02-15	Hydrate 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidyn -2, 4-dione, maleic acid salts as pharmaceutical preparation
RU2186778C2 (ru)	2002-08-10	Натриевая соль омепразола формы б, способ ее получения (варианты) и фармацевтический препарат, содержащий натриевую соль омепразола формы б
UA73974C2 (en)	2005-10-17	Hydrochloride 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, a process of preparing thereof and a pharmaceutical composition based thereon
KR100549141B1 (ko)	2006-02-03	치환된 티아졸리딘디온 유도체, 그의 제조 방법 및 제약상용도
UA67843C2 (uk)	2004-07-15	Поліморф 5-[4-[2-(n-метил-n-(2-піридил)аміно)етокси]бензил]тіазолідин-2,4-діону солі малеїнової кислоти
EA004541B1 (ru)	2004-06-24	Полиморф 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона, соли малеиновой кислоты
JP2009143954A (ja)	2009-07-02	チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
UA63980C2 (en)	2004-02-16	A hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salts
EA003031B1 (ru)	2002-12-26	Новый фармацевтический препарат
JP2009161544A (ja)	2009-07-23	チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
UA52661C2 (uk)	2003-01-15	Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
UA76721C2 (uk)	2006-09-15	Тартратні солі похідної тіазолідиндіону
UA74003C2 (en)	2005-10-17	Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, a process for preparing thereof and a pharmaceutical composition
EA005408B1 (ru)	2005-02-24	Тартратная соль производного тиазолидиндиона
BG107356A (bg)	2003-06-30	5-(4-(2-(n-метил-n-(2-пиридил)амино)етокси)бензил)тиазолидин-2,4-дион хидройодид като фармацевтиченсъстав
UA74842C2 (en)	2006-02-15	5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt and a pharmaceutical composition (variants)
UA76719C2 (uk)	2006-09-15	Тартратні солі похідної тіазолідиндіону
BG107678A (bg)	2003-11-28	Тиазолидиндионово производно и използването му като антидиабетично средство